1. Introduction
===============

Although the etiology of multiple sclerosis is still unknown, there has been a considerable expansion in understanding the pathogenesis of the disease process during the last few years ([@BIB32]). Immunological mechanisms, both cellular and humoral, seem to play a central role in the inflammatory process which leads to demyelination and destruction of oligodendrocytes in the central nervous system (CNS) ([@BIB33], [@BIB25]).

Some studies have focused on the presence of autoreactive T-lymphocytes in MS patients, and in particular on the usage of specific T-cell receptor elements for the recognition of immunodominant regions of autoantigens, such as myelin basic protein ([@BIB43] [@BIB21]). Others have assessed the role of cytokines, peptidic or glycopeptidic mediators of the immune system, during the course of the disease. [@BIB3]were the first to show that PBMC of individual MS patients produced increased amounts of IFN-*γ* and TNF-*α* at an early stage of an exacerbation of the disease, thus preceding the clinical manifestation of a relapse. These findings were later confirmed for TNF-*α* on the mRNA level ([@BIB35]). TNF-*α* is understood to play a crucial role in the upregulation of adhesion molecules on endothelial cells and leukocytes, therefore being essentially involved in T-cell migration to the sites of inflammation ([@BIB12]). Furthermore, high levels of expression of proinflammatory as well as immunosuppressive cytokines were detected in MS lesions of postmortem CNS tissue by means of immunocytochemistry ([@BIB7]).

The understanding of the role of cytokines in multiple sclerosis has become increasingly important since new treatment strategies for multiple sclerosis have emerged ([@BIB24]). Interferon beta-1b was reported to reduce exacerbation rates and the severity of exacerbations in patients with relapsing--remitting MS ([@BIB15]). However, reports on the ability to release type-I interferons upon viral stimulation in MS patients are rare.

Interferon responses of PBMC in general were shown to be diminished in patients with MS ([@BIB28], [@BIB37]), but the amount of IFN production could not be correlated with the clinical assessments of disease activity. Other authors revealed completely normal IFN-responses upon viral stimulation in MS patients ([@BIB42], [@BIB11]). Altogether, the results were largely inconclusive, since different methods have been used for IFN-induction and detection.

The aim of this study was to establish a whole blood assay in order to investigate the ability of MS patients in different stages of disease activity to produce interferons and lymphokines in response to viral or mitogenic stimulation.

2. Materials and methods
========================

2.1. Patients
-------------

We investigated 21 consecutive patients (11 males and 10 females, ages 20--57, mean age±standard deviation 37±10) fulfilling the diagnostic criteria of multiple sclerosis ([@BIB31]). Eleven patients had the relapsing--remitting course of MS, 8 patients were suffering from the secondary-progressive subtype and 2 patients had the progressive-relapsing course of the disease according to the standardized definitions ([@BIB22]). All patients were examined and classified independently by two clinical neurologists and informed consent was obtained. 10 patients were seen during an acute episode of new disease activity (acute relapse) and 11 patients were in a stable condition. An acute relapse was defined as significant worsening of preexisting symptoms as measured by the Expanded Disability Status Scale ([@BIB20]) or appearance of new neurological deficits lasting for at least 24 h. None of the patients had signs of systemic infections and plasma levels of CRP, *α* ~2~-macroglobulin and neopterin were within normal limits. The patients had not been treated with immunosuppressive drugs or steroids during the preceding 3 months before blood sampling. As a control group, we examined 20 age-matched healthy blood donors who fulfilled the criteria of the German regulations for whole blood donation.

2.2. Leukocyte count and lymphocyte subsets
-------------------------------------------

Peripheral venous blood samples were tested for whole blood and differential blood count by means of an automatic analyzer (Coulter STKS flow cytometer). Lymphocyte subpopulation analysis was performed by flow cytometry on a Coulter Epics XL/MCL flow cytometer (Coulter Electronics, Hileah, FL, USA). Following the instructions of the manufacturer, preparation and immunofluorescence staining of EDTA-anticoagulated blood samples were assisted by the Multi-Q-Prep Epics Immunology work station (Coulter, Krefeld, Germany). For gating of mononuclear lymphatic cells, we used forward and side light scatter and immunostaining with anti-CD45 (CD45-FITC/CD14-PE). For the determination of lymphocyte subpopulations such as T and B lymphocytes, CD4^+^ and CD8^+^ T-cells, activated T-cells, as well as NK cells, the following antibodies were used: CD3-ECD/CD4-PE/CD8-FITC, CD3-ECD, CD56-PE, CD16-FITC, CD3-FITC/CD19-PE, CD3-FITC and CD25-PE. MsIgG2b-ECD/MsIgG1-PE/MsIgG1-FITC, MsIgG1-FITC and MsIgG2a-PE antibodies served as controls (all antibodies were obtained from Coulter).

2.3. Whole blood assay
----------------------

Heparinized blood was drawn by vein puncture from patients and controls, stored at 4 °C and cultured in a whole blood assay within 4 h of collection according to a technique described previously ([@BIB17]). For mitogenic induction of IL-2, sIL-2R and IFN-*γ*, we used the plant lectin phytohemagglutinin (PHA, Murex Diagnostik/Burroughs Wellcome, Dartford, UK) in a final concentration of 5 μg/ml. IFN-*α* and IFN-*β* production was stimulated by Newcastle disease virus (NDV, strain Kumarov, inactivated by UV-irradiation at 366 nm for 90 min, kindly provided by R. Zawatzky, German Cancer Research Center, Heidelberg) in a final concentration of 0.8 hemagglutinating units/ml. Lipopolysaccharide (LPS) (Sigma, Deisenhofen, FRG), consisting of purified Escherichia coli OIII:B4 endotoxin, was used for the induction of TNF-*α* at a final concentration of 1 μg/ml. 100 μl whole blood was mixed with 850 μl culture medium (Seromed RPMI 1640, 20 mM Hepes; Biochrom, Berlin, Germany) supplemented with 2 mM [l]{.smallcaps}-glutamine, 100 U of penicillin per ml, and 100 μl of streptomycin per ml (Gibco, Karlsruhe, Germany) in 5 ml PPN test tubes (Greiner, Nürtingen, Germany). 50 μl of the appropriate mitogen solution was added for the induction of cytokine production. As negative control, we tested the cytokine production in unstimulated cultures. Tubes were covered and incubated in a humidified atmosphere of 5% CO~2~ at 37 °C. Supernates were harvested after 48 h (IL-2, TNF-*α*, IFN-*α*, IFN-*β*) and 96 h (IFN-*γ* and sIL-2R) and stored frozen at −80 °C until assayed.

2.4. Cytokine measurement
-------------------------

The concentrations of cytokines in the supernates of cell cultures were determined by means of quantitative enzyme-linked immunosorbent assay (ELISA). IFN-*α* was additionally determined in sera samples of the individual patients. ELISA kits for IFN-*α* (intraassay variance 3.7%, interassay variance 5.3%), IFN-*γ* (intraassay variance 5.2%, interassay variance 6.0%), TNF-*α* (intraassay variance 3.5%, interassay variance 4.0%) and IL-2 (intraassay variance 3.9%, interassay variance 5.5%) were obtained from Bio Source International (Camarillo, CA, USA). The ELISA kit for detection of sIL-2R (intraassay variance 3.6%, interassay variance 2.0%) was obtained from R&D Systems (Minneapolis, MN, USA) and for IFN-*β* (intraassay variance 4.1%, interassay variance 3.7%) from Medgenix Diagnostics (Ratingen, Germany). Serial dilutions of samples and standards were incubated in microtiter wells and the assays were performed as described in the manufacturer\'s protocol. The color intensity was measured photometrically in an ELISA reader (Anthos Labtec, Salzburg, Austria). Individual concentrations could be determined from a standard curve. Minimal detectable doses were 5 pg/ml (TNF-*α*, IFN-*α*, IFN-*γ*, IL-2, sIL-2R) and 3 units/ml (IFN-*β*), respectively.

2.5. Statistics
---------------

Statistical analysis was performed using commercially available software for personal computers (SPSS for Windows 5:01, SPSS GmbH Software, Munich, Germany). The Mann-Whitney-U test was used to compare non-parametrically distributed data between patient and control groups. *p* values\<0.05 were considered to be significant.

3. Results
==========

3.1. Differential blood cell count and lymphocyte subpopulations
----------------------------------------------------------------

Differential blood cell counts showed no significant differences between the two patient groups ([Table 1](#TBL1){ref-type="table"} ) and were all within normal ranges. With regard to the lymphocyte subpopulations, we found a significantly lower amount of CD8^+^ T-cells in patients with stable disease, leading to a significantly higher CD4/CD8 ratio in this patient group as compared to MS patients undergoing an acute exacerbation (*p*\<0.03).Table 1Differential blood cell counts and lymphocyte subpopulations of MS-patients with acute exacerbation and stable diseaseAcute exacerbationStable disease(*n*=10)(*n*=11)Differential blood cell counts (cells/μl) Leukocytes7140±20007800±3600 Monocytes530±150470±190 Neutrophils4330±16005490±2870 Lymphocytes1980±6201600±600Lymphocyte subpopulation (lymphocytes/μl) CD3 T cells1536±6421198±443 CD3, CD25 activated T cells (%)5.3±2.15.6±2.8 CD4 T cells948±372870±362 CD8 T cells409±109276±134^\*^ CD4:CD8 cell ratio2.3±0.53.4±1.1^\*^ CD19 B cells268±150209±149 CD16, CD56 NK cells196±101169±106[^1]

3.2. Cytokine production after mitogenic stimulation
----------------------------------------------------

Measurement of IFN-*γ*, TNF-*α* and sIL-2R in the supernates of mitogen-stimulated whole-blood cultures revealed no significant differences in cytokine production between patient groups and controls ([Table 2](#TBL2){ref-type="table"} ). The results of the in vitro production of IL-2 after mitogenic stimulation are shown in [Fig. 1](#FIG1){ref-type="fig"} . Interestingly, both patient groups showed a significantly (*p*\<0.005) decreased IL-2 production in comparison to the control group.Table 2Cytokine production in a whole-blood assay in MS patients with acute exacerbation (*n*=10), with stable disease (*n*=11) and controls (*n*=20)CytokineMS (acute exacerbation)MS (stable)ControlsTNF-*α* (pg/ml)122.6±76.3100.1±50.2128.1±82.4IFN-*γ* (pg/ml)3755±3488.12358.5±1760.74494.8±3207.9sIL-2R (pg/ml)5492.7±23025318.4±23744691±1673[^2]Fig. 1Interleukin-2 production in patients (*n*=10) with acute exacerbation (A), patients (*n*=11) with stable disease (B) and control (*n*=20) group (C). Each open figure represents the average of duplicate determination of interleukin-2 in the supernates of (PHA)-stimulated cell cultures. The horizontal bars represent mean interleukin-2 levels in each patient group.

In contrast, NDV induced production of IFN-*α* showed highly significant differences in mean values between the two patient groups. Patients with stable disease (156.6 pg/ml) produced significantly (*p*\<0.0001) lower amounts of IFN-*α* than controls (924.1 pg/ml) and patients with disease activity (773.6 pg/ml). No influence of age and sex was observed. Results are shown in [Fig. 2](#FIG2){ref-type="fig"} . No IFN-*α* was detectable in sera samples of the patients.Fig. 2Interferon-*α* production in patients (*n*=10) with acute exacerbation (A), patients (*n*=11) with stable disease (B) and control (*n*=20) group (C).

Detection of NDV induced IFN-*β* secretion revealed similar results ([Fig. 3](#FIG3){ref-type="fig"} ). Overall, IFN-*β* was produced in lower amounts than IFN-*α*. However, the mean value in patients with stable disease (8.0 U/ml) was also significantly lower than in patients with disease activity (52.6 U/ml) and controls (29.6 U/ml).Fig. 3Interferon-*β* production in patients (*n*=10) with acute exacerbation (A), patients (*n*=11) with stable disease (B) and control (*n*=20) group (C).

No cytokines were detectable in the supernates of unstimulated cultures.

4. Discussion
=============

The present study revealed a remarkable decrease in production of IFN-*α* and IFN-*β* upon viral stimulation in PBMC of MS patients with stable disease and an impaired ability to secrete IL-2 in all MS patients irrespective of disease activity. Production of IFN-*γ* and TNF-*α* did not differ from values observed in the control group, and titers of sIL-2R were not increased in the patient group either. Additionally, MS patients with stable disease showed a significantly lower number of CD8^+^ T-cells.

In previous publications, low IFN responses to various viral antigens have occasionally been described for MS patients ([@BIB28] [@BIB37]). However, the findings were not related to the clinical stage of the disease activity. [@BIB1]showed an association of low IFN-*α* responsiveness with the MHC allele HLA-DR2, which is over-represented in MS patients ([@BIB14]). The defective IFN response could therefore possibly be related to the genetic background of MS patients. In the present study, however, diminished production of IFN-*α* and IFN-*β* was exclusively observed in MS patients with stable disease. Patients admitted to hospital during an acute attack revealed normal IFN-*α* and IFN-*β* values.

In response to viral stimulation, PBMC produce mainly IFN-*α* and a small proportion of IFN-*β* ([@BIB6]). The two interferons have similar biological and physicochemical properties, are structurally related ([@BIB18]), and are, therefore, classified as type-I interferons. However, there are striking homologies within the coding as well as flanking regions of the IFN-*α* and IFN-*β* genes, both located on chromosome 9 of the human genome. Our findings suggest a primary deficit in type-I IFN response in MS patients which may render them susceptible to factors causing exacerbations of the disease.

Since interferons are the only cytokines with clear antiviral potency, viruses might be responsible for triggering the pathophysiological processes leading to an exacerbation in MS. One possible mechanism could be initiated by a virus with tropism to the central nervous system, leading to destruction of myelin sheaths and triggering off an immune response to released autoantigens, such as myelin basic protein (MBP). In this regard, coronavirus and human herpesvirus-6 are currently of interest on the basis of polymerase chain reaction and immunohistochemical studies of MS brains ([@BIB8]).

Molecular mimicry, i.e. an immune response against a foreign antigen with some resemblance to a host protein, could be another mechanism for the induction of an autoaggressive T-cell response. Recent studies have pointed out that MBP specific T-cells from MS patients crossreact with peptides from diverse viral agents ([@BIB34], [@BIB44]).

The clinical observation that viral infections are frequently associated with or followed by acute MS relapses also suggests that an activation of the peripheral immune compartment may contribute to an acceleration of disease progression ([@BIB40], [@BIB30]). Interestingly, acyclovir, an antiviral drug, has recently been reported to significantly reduce exacerbation rates in MS ([@BIB23]).

The question arises, however, as to what causes type-I IFN low responsiveness in MS patients and what are the mechanisms involved in upregulation of IFN-*α* and IFN-*β* gene expression in the course of a relapse. Serial studies in individual patients are required to reveal if type-I IFN production increases at the beginning of an attack or if it leads to its remission. The positive effect of treatment with IFN-*β* and IFN-*α* ([@BIB10], [@BIB16]) could then possibly be regarded as substitution of a preexisting deficit.

The second striking feature of this study was defective production of interleukin-2 in all MS patients regardless of their clinical state. In previous studies, an impairment of IL-2 production was predominantly described for MS patients with stable disease ([@BIB39]). Interleukin-2 is produced by activated helper T-cells and is required for appropriate lymphocyte function and proliferation ([@BIB41]). Defective production of IL-2 therefore results in an impaired T-cell response and diminished protection against viral infections. Similar findings have been reported for a variety of autoimmune diseases, e.g. diabetes mellitus ([@BIB45], [@BIB36]) or Sjögren\'s syndrome ([@BIB27]) and also for other neurological disorders like Parkinson\'s disease ([@BIB19]). Interleukin-2 further acts as an endogenous brain neurokine which is able to influence central nervous functions ([@BIB13], [@BIB26]). Interleukin-2 mRNA has recently been found to be present in human oligodendrocytes ([@BIB29]), implicating a role for IL-2 in the development of oligodendrocytes, their MBP content and reconstitution ([@BIB4], [@BIB38], [@BIB5]).

Studies on cytokine patterns within postmortem CNS specimens, however, revealed high levels of IL-2 expression in acute MS-lesions ([@BIB7]). Thus, decreased amounts of IL-2 in the supernates of stimulated cell cultures could also result from increased binding of the cytokine to its receptor on activated T-cells, indicating higher in vitro proliferation upon mitogenic stimulation in MS patients as compared to healthy controls.

Decreased numbers of CD8^+^ T-cells in MS patients have repeatedly been observed by others ([@BIB9]). Our results support the hypothesis that CD8^+^ T-cell mediated suppressor function is lost before and during MS attacks and recovers with remission ([@BIB2]).

Interestingly, we did not find significant differences in the production of TNF-*α* and IFN-*γ* between the two patient groups in this cross-sectional study. Since IFN-*γ* and IL-2 are both produced by activated T-lymphocytes, the impaired IL-2 production may implicate a selective inhibitory mechanism that may downregulate IL-2 but not IFN-*γ* secretion of this T-cell subpopulation in MS patients. However, an involvement of NK-cells, being known as IL-2 producers, can not be excluded.

Investigating CNS specimens from MS patients, [@BIB7]found high expression of TNF-*α* in acute and chronic plaques, thus stressing its role in the pathogenesis of the disease. In their study, however, TNF-*α* was mainly produced by microglial cells and by foamy macrophages within the lesions, i.e. cells which are not detectable in the peripheral blood.

In conclusion, we found abnormalities in the IFN-*α* and IFN-*β* response of MS patients in relation to disease activity and in their ability to produce IL-2. The etiology of these immunological deficits is unknown. We conclude that the selective immunological abnormalities in MS patients provide the background for disease susceptibility, progression and exacerbation, possibly triggered by diverse exogenous factors, e.g. viruses. The individual production of endogenous type-I IFNs in MS patients may be a useful tool for monitoring disease activity and for studying the underlying pathophysiology.
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[^1]: Values are given as means±standard deviations.

    ^\*^ *p*\<0.03.

[^2]: Values are given as means±standard deviations.
